8-K: Neuraxis Stockholders Approve Director Slate, Auditor, and Series B Preferred Stock Conversion

Neuraxis, Inc. announced that its stockholders approved all proposals at the Annual Meeting held on May 29, 2025, including the election of six directors, ratification of its independent auditor, and the issuance of common stock upon conversion of Series B Preferred Stock.

Summary

• Neuraxis, Inc. held its Annual Meeting of Stockholders on May 29, 2025, with a quorum of 5,660,885 votes, representing approximately 59.22% of outstanding votes.
• Six nominees for director were elected to serve a one-year term, with 'For' votes ranging from 94.41% to 99.82%.
• The appointment of Rosenberg Rich Baker Berman, P.A. as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with 5,655,664 votes 'For'.
• A proposal for the issuance of 20% or more of the company's outstanding Common Stock upon the conversion of Series B Convertible Preferred Stock was approved with 4,127,496 votes 'For'.

Sentiment

Score: 7

Explanation: The sentiment is generally positive as all management-backed proposals passed successfully with strong shareholder support, indicating stability in corporate governance and capital structure management.

Positives

• All six director nominees were successfully elected with strong shareholder support, indicating stable leadership.
• The appointment of the independent registered public accounting firm was overwhelmingly approved, demonstrating good corporate governance and financial oversight.
• The proposal to allow for the conversion of Series B Preferred Stock into Common Stock was approved, providing clarity on the company's capital structure going forward.
• A quorum of 59.22% of outstanding votes was achieved, ensuring the validity of the meeting's proceedings.

Future Outlook

The approval of the proposal regarding the issuance of common stock upon conversion of Series B Convertible Preferred Stock indicates a future potential increase in the number of outstanding common shares, which could lead to dilution for existing common stockholders.

Management Comments

• Brian Carrico, President and Chief Executive Officer, signed the report on behalf of Neuraxis, Inc.

Industry Context

This filing is a standard procedural update for a publicly traded company, reporting the outcomes of its annual shareholder meeting. The approval of director elections and auditor ratification are routine governance matters, while the Series B conversion proposal is specific to Neuraxis's capital structure management.

Comparison to Industry Standards

• The high approval rates for director elections (94.41% to 99.82%) and auditor ratification (nearly 100% of votes cast) are generally in line with typical shareholder meeting outcomes for established public companies, indicating strong shareholder confidence in management and governance.
• Achieving a quorum of 59.22% is a healthy participation rate for an annual meeting, comparable to many companies of similar size and market capitalization.

Corporate Governance

Stakeholder Impact

• Shareholders: Directly impacted by the election of directors who will oversee company strategy and governance. Common stockholders face potential future dilution from the conversion of Series B Preferred Stock.
• Management: The re-election of directors, including the CEO, provides continuity and a clear mandate for the current leadership.

Next Steps

• The elected directors will serve a one-year term.
• Rosenberg Rich Baker Berman, P.A. will serve as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The company is now authorized to issue common stock upon the conversion of Series B Convertible Preferred Stock, which may occur in the future.

Key Dates

Recommendation

Keywords

Neuraxis, NRXS, Annual Meeting, Stockholders Meeting, Director Election, Auditor Ratification, Series B Preferred Stock, Common Stock Conversion, Corporate Governance, SEC Filing, 8-K